ACCA SBR — Strategic Business Reporting Practice Exam 1

SECTION A

Background:
AeroGrid Group is a rapidly expanding multinational entity operating in the renewable energy sector. Its functional and presentation currency is the Dollar ($). On 1 January 20X4, AeroGrid acquired a 30% equity interest in BreezeTech, a wind-turbine manufacturer located in a foreign jurisdiction whose functional currency is the Krona (KR). This investment gave AeroGrid significant influence, and it was correctly accounted for as an associate. The cost of the 30% investment was $40 million.

On 1 July 20X4, AeroGrid acquired a further 50% of the equity shares in BreezeTech for a cash consideration of $120 million, achieving control.

Additional Information at 1 July 20X4:

1. The fair value of AeroGrid's previously held 30% interest in BreezeTech was determined to be $65 million.
2. The fair value of the identifiable net assets of BreezeTech was $180 million.
3. AeroGrid has chosen to measure the non-controlling interest (NCI) in BreezeTech at fair value. The fair value of the 20% NCI at 1 July 20X4 was $45 million.
4. BreezeTech's net assets included an unrecognised internally generated patent for blade aerodynamics. The fair value of this patent was reliably measured at $15 million and is included in the $180 million net asset valuation.

Year-End Translation (31 December 20X4):
BreezeTech's operations are highly autonomous. At the year-end, the exchange rates fluctuated significantly. AeroGrid's directors are unsure how to treat the goodwill arising on acquisition and the fair value adjustments when translating BreezeTech's financial statements into Dollars for consolidation purposes.

Required:

(a) Discuss the financial reporting principles under IFRS 3 Business Combinations for accounting for the step acquisition of BreezeTech on 1 July 20X4, including the treatment of the previously held equity interest. (10 marks)

(b) Calculate the goodwill arising on the acquisition of BreezeTech on 1 July 20X4, and explain the recognition of the internally generated patent in the consolidated financial statements. (10 marks)

(c) Advise the directors of AeroGrid on the application of IAS 21 The Effects of Changes in Foreign Exchange Rates regarding the translation of BreezeTech's results, goodwill, and fair value adjustments at the year-end 31 December 20X4. (10 marks)

SECTION A

Background:
NovaGene is a highly innovative biotechnology startup. The company is currently seeking a Series B funding round from venture capitalists. The funding is contingent upon NovaGene demonstrating a strong balance sheet and meeting specific asset-to-debt covenants.

During the year ended 31 March 20X5, NovaGene incurred $8 million in costs related to early-stage clinical trials for a new gene therapy. The technical feasibility of the therapy is still highly uncertain, and regulatory approval is at least three years away. The CFO has instructed the financial accountant to capitalise $5 million of these costs as 'Development Expenditure' under IAS 38 Intangible Assets, arguing that the therapy has massive commercial potential.

Furthermore, to improve liquidity, the CFO arranged a transaction involving NovaGene's main laboratory building. The building was 'sold' to a financial institution for $20 million (its fair value) and immediately leased back for 15 years. The lease terms dictate that NovaGene retains all risks and rewards of the building, and there is a mandatory repurchase clause at the end of the lease term. The CFO has instructed the accountant to derecognise the building and recognise the $20 million as revenue from a contract with a customer under IFRS 15.

The financial accountant is a qualified ACCA member and feels uncomfortable with these instructions.

Required:

(a) Discuss the correct financial reporting treatment for the clinical trial costs (IAS 38) and the sale and leaseback transaction (IFRS 15 / IFRS 16). (12 marks)

(b) Evaluate the ethical issues faced by the financial accountant and advise on the appropriate actions they should take in accordance with the ACCA Code of Ethics and Conduct. (8 marks)

SECTION B

Background:
Ceres AgriCorp is a large-scale commercial farming enterprise specialising in viticulture (wine production). The company owns extensive vineyards.

During the current reporting period, Ceres AgriCorp has faced two significant accounting issues:

Issue 1: Biological Assets
Ceres owns grapevines that have an expected productive life of 40 years. At the reporting date, the vines are bearing a heavy crop of grapes that are two weeks away from harvest. The directors are confused about whether the grapevines and the unharvested grapes should be accounted for under IAS 16 Property, Plant and Equipment or IAS 41 Agriculture, and how changes in fair value should be recognised.

Issue 2: Climate Change and Impairment
Ceres operates a large grape-processing facility. Recently, the region has experienced severe, unprecedented droughts linked to climate change, which are expected to reduce crop yields by 20% over the next decade and increase water procurement costs significantly. The directors are preparing a value-in-use (VIU) calculation to test the processing facility for impairment under IAS 36 Impairment of Assets. They have currently excluded the increased water costs from the cash flow projections, arguing they are 'future restructuring costs'.

Stakeholder Perspective:
Institutional investors have expressed frustration with Ceres AgriCorp's financial statements, noting that the profit or loss figure is highly volatile and makes it difficult to assess the underlying cash-generating performance of the business.

Required:

(a) Advise the directors on the correct accounting treatment for the grapevines and the unharvested grapes under IFRS standards. (8 marks)

(b) Discuss how the climate change risks should be incorporated into the impairment review of the processing facility under IAS 36, and evaluate the directors' decision to exclude the increased water costs. (9 marks)

(c) Explain to the directors why institutional investors might find the fair value accounting of biological assets challenging when interpreting the financial statements, and how investors might adjust their analysis. (8 marks)

SECTION B

Background:
Quantum Logistics is a global shipping and freight forwarding company. The company is exposed to significant volatility in marine fuel prices.

Issue 1: Hedge Accounting
On 1 October 20X4, to protect against rising fuel costs for a highly probable forecast voyage in March 20X5, Quantum entered into a forward contract to purchase 10,000 metric tons of marine fuel at a fixed price. Quantum designated this forward contract as a cash flow hedge under IFRS 9 Financial Instruments. At the year-end of 31 December 20X4, the fair value of the forward contract had increased by $400,000 due to rising global fuel prices. The hedge is determined to be 100% effective.

Issue 2: Restructuring Provision
Due to advancements in automated port logistics, Quantum's board of directors decided on 15 December 20X4 to close three of its European manual sorting hubs. A detailed formal plan was drafted. On 20 December 20X4, the board sent a letter to all affected employees notifying them of the impending redundancies and hub closures. The estimated redundancy costs are $2.5 million, and the cost of retraining staff to use the new automated systems is estimated at $500,000.

Issue 3: Variable Consideration
Quantum frequently charges its clients 'demurrage' fees. These are penalty fees charged if a client takes too long to load or unload a shipping container. Demurrage is highly variable and depends on port congestion and client efficiency. Historically, Quantum only recognised demurrage revenue when the cash was received.

Required:

(a) Explain the criteria for applying hedge accounting under IFRS 9, and detail how the forward contract should be accounted for in Quantum's financial statements for the year ended 31 December 20X4. (9 marks)

(b) Discuss whether Quantum should recognise a provision for the restructuring under IAS 37 Provisions, Contingent Liabilities and Contingent Assets at 31 December 20X4, and determine the amount to be recognised. (8 marks)

(c) Advise Quantum on how to account for the demurrage fees under IFRS 15 Revenue from Contracts with Customers, specifically addressing the treatment of variable consideration. (8 marks)